ORGANOGENESIS HOLDINGS INC (ORGO) Fundamental Analysis & Valuation

NASDAQ:ORGO • US68621F1021

2.66 USD
+0.01 (+0.38%)
Last: Mar 13, 2026, 09:45 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ORGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall ORGO gets a fundamental rating of 5 out of 10. We evaluated ORGO against 519 industry peers in the Biotechnology industry. While ORGO has a great profitability rating, there are some minor concerns on its financial health. ORGO has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. ORGO Profitability Analysis

1.1 Basic Checks

  • In the past year ORGO was profitable.
  • In the past year ORGO has reported a negative cash flow from operations.
  • ORGO had positive earnings in 4 of the past 5 years.
  • ORGO had a positive operating cash flow in 4 of the past 5 years.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 2.65%, ORGO belongs to the top of the industry, outperforming 88.82% of the companies in the same industry.
  • The Return On Equity of ORGO (3.65%) is better than 89.98% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 8.83%, ORGO belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 19.44%.
  • The 3 year average ROIC (5.16%) for ORGO is below the current ROIC(8.83%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROIC 8.83%
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • Looking at the Profit Margin, with a value of 2.81%, ORGO belongs to the top of the industry, outperforming 88.63% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ORGO has declined.
  • ORGO's Operating Margin of 9.90% is amongst the best of the industry. ORGO outperforms 90.56% of its industry peers.
  • ORGO's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 75.62%, ORGO belongs to the best of the industry, outperforming 83.24% of the companies in the same industry.
  • ORGO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ORGO Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ORGO is creating some value.
  • ORGO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ORGO has been reduced compared to 5 years ago.
  • Compared to 1 year ago, ORGO has a worse debt to assets ratio.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ORGO has an Altman-Z score of 3.01. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
  • ORGO has a Altman-Z score of 3.01. This is in the better half of the industry: ORGO outperforms 67.05% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that ORGO is not too dependend on debt financing.
  • ORGO has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 3.01
ROIC/WACC1.02
WACC8.69%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • ORGO has a Current Ratio of 3.62. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.62, ORGO is in line with its industry, outperforming 42.97% of the companies in the same industry.
  • A Quick Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
  • The Quick ratio of ORGO (3.32) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.32
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ORGO Growth Analysis

3.1 Past

  • ORGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.94%, which is quite impressive.
  • Measured over the past years, ORGO shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.72% on average per year.
  • The Revenue has grown by 17.04% in the past year. This is quite good.
  • The Revenue has been growing by 10.77% on average over the past years. This is quite good.
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%

3.2 Future

  • ORGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.92% yearly.
  • ORGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.93% yearly.
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.34%
Revenue Next 2Y3.93%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. ORGO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 10.23, which indicates a very decent valuation of ORGO.
  • ORGO's Price/Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 97.11% of the companies in the same industry.
  • ORGO is valuated cheaply when we compare the Price/Earnings ratio to 25.71, which is the current average of the S&P500 Index.
  • ORGO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 10.23
Fwd PE N/A
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaper than 99.04% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.62
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • The decent profitability rating of ORGO may justify a higher PE ratio.
  • ORGO's earnings are expected to grow with 12.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)0.61
EPS Next 2Y12.92%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ORGO Dividend Analysis

5.1 Amount

  • ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORGO Fundamentals: All Metrics, Ratios and Statistics

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (3/13/2026, 9:45:16 AM)

2.66

+0.01 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners54.15%
Inst Owner Change-0.51%
Ins Owners32.49%
Ins Owner Change1.24%
Market Cap342.18M
Revenue(TTM)564.17M
Net Income(TTM)15.85M
Analysts85
Price Target8.67 (225.94%)
Short Float %19.4%
Short Ratio15.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.05%
Min EPS beat(2)44.72%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)16.53%
Min EPS beat(4)-73%
Max EPS beat(4)167.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.19%
Min Revenue beat(2)10.3%
Max Revenue beat(2)28.08%
Revenue beat(4)2
Avg Revenue beat(4)6.94%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)28.08%
Revenue beat(8)6
Avg Revenue beat(8)7.04%
Revenue beat(12)7
Avg Revenue beat(12)4.32%
Revenue beat(16)7
Avg Revenue beat(16)2.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-111.11%
EPS NQ rev (3m)-111.11%
EPS NY rev (1m)-117.24%
EPS NY rev (3m)-117.24%
Revenue NQ rev (1m)-26.28%
Revenue NQ rev (3m)-26.28%
Revenue NY rev (1m)-13.79%
Revenue NY rev (3m)-13.79%
Valuation
Industry RankSector Rank
PE 10.23
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.86
EV/EBITDA 3.62
EPS(TTM)0.26
EY9.77%
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS4.39
BVpS3.37
TBVpS3.08
PEG (NY)N/A
PEG (5Y)0.61
Graham Number4.44
Profitability
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROCE 11.21%
ROIC 8.83%
ROICexc 10.88%
ROICexgc 12%
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
FCFM N/A
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ROICexc(3y)6.81%
ROICexc(5y)10.02%
ROICexgc(3y)7.75%
ROICexgc(5y)12.19%
ROCE(3y)6.54%
ROCE(5y)9.15%
ROICexgc growth 3Y14.91%
ROICexgc growth 5Y-14%
ROICexc growth 3Y18.93%
ROICexc growth 5Y-6.02%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
F-Score2
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.17
Cap/Depr 76.1%
Cap/Sales 2.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 3.32
Altman-Z 3.01
F-Score2
WACC8.69%
ROIC/WACC1.02
Cap/Depr(3y)97.86%
Cap/Depr(5y)180.1%
Cap/Sales(3y)3.4%
Cap/Sales(5y)4.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%
Revenue Next Year-8.34%
Revenue Next 2Y3.93%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y159.64%
EBIT growth 3Y35.82%
EBIT growth 5Y15.91%
EBIT Next Year-3.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-685.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.56%
OCF growth 3YN/A
OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC / ORGO FAQ

Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to ORGO.


Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.


What is the profitability of ORGO stock?

ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 7 / 10.


What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?

The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.